“We are excited to begin working with Moderna on a specific application of our AI-enabled cryo-EM platform that leverages our technology infrastructure and deep experience in structural biology and medicinal chemistry,” said Sriram Subramaniam, Ph.D., Founder and CEO of Gandeeva Therapeutics. “Through our internal pipeline programs and collaborations, we are aggressively pursuing the development of first-in-class modalities in targeting difficult-to-drug protein-protein interactions.”

Under the research agreement, Gandeeva and Moderna will study and validate the application of Gandeeva’s proprietary cryo-EM platform approach for an undisclosed Moderna target. Gandeeva will receive research payments from Moderna. Additional terms of the agreement were not disclosed.